干旱区生态环境知识资源中心(Arid): Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities

Arid

DOI	10.1038/s41416-023-02361-4
	Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities
	Wang, Mona Meng; Coupland, Sarah E.; Aittokallio, Tero; Figueiredo, Carlos R.
通讯作者	Figueiredo, CR
来源期刊	BRITISH JOURNAL OF CANCER
ISSN	0007-0920
EISSN	1532-1827
出版年	2023
卷号	129 期号:8 页码:1212-1224
英文摘要	Immune checkpoint therapies (ICT) can reinvigorate the effector functions of anti-tumour T cells, improving cancer patient outcomes. Anti-tumour T cells are initially formed during their first contact (priming) with tumour antigens by antigen-presenting cells (APCs). Unfortunately, many patients are refractory to ICT because their tumours are considered to be 'cold' tumours-i.e., they do not allow the generation of T cells (so-called 'desert' tumours) or the infiltration of existing anti-tumour T cells (T-cell-excluded tumours). Desert tumours disturb antigen processing and priming of T cells by targeting APCs with suppressive tumour factors derived from their genetic instabilities. In contrast, T-cell-excluded tumours are characterised by blocking effective anti-tumour T lymphocytes infiltrating cancer masses by obstacles, such as fibrosis and tumour-cell-induced immunosuppression. This review delves into critical mechanisms by which cancer cells induce T-cell 'desertification' and 'exclusion' in ICT refractory tumours. Filling the gaps in our knowledge regarding these pro-tumoral mechanisms will aid researchers in developing novel class immunotherapies that aim at restoring T-cell generation with more efficient priming by APCs and leukocyte tumour trafficking. Such developments are expected to unleash the clinical benefit of ICT in refractory patients.
类型	Review
语种	英语
开放获取类型	hybrid, Green Published
收录类别	SCI-E
WOS记录号	WOS:001025858500001
WOS关键词	CATENIN PATHWAY ACTIVATION ; METASTATIC UVEAL MELANOMA ; COLONY-STIMULATING FACTOR ; DENDRITIC CELLS ; CANCER-IMMUNOTHERAPY ; ANTITUMOR IMMUNITY ; PLUS IPILIMUMAB ; ANTIGEN ; BLOCKADE ; EXPRESSION
WOS类目	Oncology
WOS研究方向	Oncology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/395617
推荐引用方式 GB/T 7714	Wang, Mona Meng,Coupland, Sarah E.,Aittokallio, Tero,et al. Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities[J],2023,129(8):1212-1224.
APA	Wang, Mona Meng,Coupland, Sarah E.,Aittokallio, Tero,&Figueiredo, Carlos R..(2023).Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities.BRITISH JOURNAL OF CANCER,129(8),1212-1224.
MLA	Wang, Mona Meng,et al."Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities".BRITISH JOURNAL OF CANCER 129.8(2023):1212-1224.